Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Genitourinary 3Tumor-Agnostic 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Carcinoma 2Neoplasms 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × trebananib × Gynecologic × Clear all
NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Dana-Farber Cancer Institute

Phase 1 Completed
62 enrolled 17 charts
DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT01253681 2015-10-14

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Amgen

Phase 1 Completed
27 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Amgen

Phase 1 Completed
103 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡